Myovant Sciences Ltd (MYOV) is a biopharmaceutical company that develops innovative treatments for women's health and endocrine diseases. The company's lead product candidate, relugolix, is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that is being developed for the treatment of uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Myovant Sciences is also developing other product candidates, including MVT-602, a kisspeptin agonist for the treatment of female infertility, and MVT-602-2, a kisspeptin antagonist for the treatment of hormone-dependent breast cancer. The company is headquartered in London, United Kingdom, and as of September 2021, had a market capitalization of approximately $3.5 billion.
Myovant Sciences Ltd (MYOV) is a biopharmaceutical company that develops innovative treatments for women's health and endocrine diseases. The company's lead product candidate, relugolix, is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that is being developed for the treatment of uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Myovant Sciences is also developing other product candidates, including MVT-602, a kisspeptin agonist for the treatment of female infertility, and MVT-602-2, a kisspeptin antagonist for the treatment of hormone-dependent breast cancer. The company is headquartered in London, United Kingdom, and as of September 2021, had a market capitalization of approximately $3.5 billion.